ADMA Biologics, Inc. (ADMA) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
ADMA's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
ADMA Revenue Analysis (2013–2024)
As of February 28, 2026, ADMA Biologics, Inc. (ADMA) generated trailing twelve-month (TTM) revenue of $488.6 million, reflecting strong growth of +12.0% year-over-year. The most recent quarter (Q3 2025) recorded $134.2 million in revenue, up 10.0% sequentially.
Looking at the longer-term picture, ADMA's 5-year compound annual growth rate (CAGR) stands at +70.8%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $426.5 million in 2024, representing a new all-time high.
Revenue diversification analysis shows ADMA's business is primarily driven by ADMA BioManufacturing Segment (97%), and Plasma Collection Centers Segment (3%). With over half of revenue concentrated in ADMA BioManufacturing Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including UTHR (+10.6% YoY), ZLAB (+15.3% YoY), and AMRN (-6.2% YoY), ADMA has underperformed the peer group in terms of revenue growth. Compare ADMA vs UTHR →
Peer Comparison
Compare ADMA's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ADMACurrent | $489M | +12.0% | +70.8% | 32.6% | |
| UTHR | $3.2B | +10.6% | +16.5% | 46.9% | |
| ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
| AMRN | $229M | -6.2% | -11.9% | -40.2% | |
| ALKS | $1.5B | -5.2% | +7.3% | 17.2% | |
| ARQT | $376M | +91.3% | - | -3.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $426.5M | +65.2% | $219.6M | 51.5% | $139.0M | 32.6% |
| 2023 | $258.2M | +67.6% | $88.9M | 34.4% | $21.6M | 8.4% |
| 2022 | $154.1M | +90.4% | $35.3M | 22.9% | $-39,365,000 | -25.5% |
| 2021 | $80.9M | +91.7% | $1.2M | 1.4% | $-58,374,000 | -72.1% |
| 2020 | $42.2M | +43.9% | $-19,071,643 | -45.2% | $-64,914,877 | -153.8% |
| 2019 | $29.3M | +72.8% | $-10,155,155 | -34.6% | $-41,424,327 | -141.1% |
| 2018 | $17.0M | -25.4% | $-25,209,345 | -148.4% | $-60,288,944 | -354.9% |
| 2017 | $22.8M | +113.5% | $-6,403,761 | -28.1% | $-39,309,996 | -172.7% |
| 2016 | $10.7M | +48.5% | $4.3M | 40.3% | $-17,330,395 | -162.6% |
| 2015 | $7.2M | +21.3% | $2.9M | 39.9% | $-15,513,807 | -216.1% |
See ADMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADMA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ADMA vs AGIO
See how ADMA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ADMA's revenue growth accelerating or slowing?
ADMA maintains +12.0% revenue growth, in line with its 5-year CAGR of +70.8%. TTM revenue stands at $489M. Growth rate remains consistent with historical average.
What is ADMA's long-term revenue growth rate?
ADMA Biologics, Inc.'s 5-year revenue CAGR of +70.8% reflects the sustained expansion pattern. Current YoY growth of +12.0% is near this long-term average.
How is ADMA's revenue distributed by segment?
ADMA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.